Bridget E. Karlin
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Lumexa Imaging (LMRI) Valuation Analysis Published. A recent analysis suggests Lumexa Imaging Holdings may be trading at a discount to its estimated fair value, citing the company's imaging growth story. The stock is currently trading below the average analyst target price of $17.57. This valuation perspective provides context for investors assessing the company's current market position relative to its long-term potential.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Dana Gets EU Approval For Eaton Mobility Deal. Dana Incorporated has received European Commission approval to acquire Eaton's mobility operations. This regulatory green light is a key step in finalizing the transaction, which aims to expand Dana's presence in the European market. The approval removes a major uncertainty that had been weighing on the deal's timeline.
Transaction History
| LYB | ▲ Buy | Grant | 781 | $0 | 9/30/2026 | View on chart |
| LYB | ▼ Sell | Tax Withholding | 194 | $11K | 9/30/2026 | View on chart |
| LYB | ▲ Buy | Grant | 615 | $0 | 6/30/2026 | View on chart |
| LYB | ▼ Sell | Tax Withholding | 73 | $4K | 6/30/2026 | View on chart |
| LMRI | ▲ Buy | Grant | 19,358 | $0 | 6/10/2026 | View on chart |
| LYB | ▼ Sell | Tax Withholding | 521 | $36K | 5/22/2026 | View on chart |
| LYB | ▲ Buy | Grant | 2,321 | $0 | 5/21/2026 | View on chart |
| LYB | ▲ Buy | Grant | 708 | $0 | 3/31/2026 | View on chart |
| LYB | ▼ Sell | Tax Withholding | 111 | $9K | 3/31/2026 | View on chart |
| DAN | ▲ Buy | Option Exercise | 10,104 | $0 | 2/11/2026 | View on chart |
| DAN | ▲ Buy | Option Exercise | 227 | $0 | 2/11/2026 | View on chart |
| LYB | ▼ Sell | Tax Withholding | 303 | $17K | 5/24/2025 | View on chart |
| LYB | ▲ Buy | Grant | 2,917 | $0 | 5/22/2025 | View on chart |
| DAN | ▲ Buy | Option Exercise | 12,359 | $0 | 2/14/2025 | View on chart |
| DAN | ▲ Buy | Option Exercise | 425 | $0 | 2/14/2025 | View on chart |
| LYB | ▲ Buy | Grant | 1,694 | $0 | 5/24/2024 | View on chart |
| DAN | ▲ Buy | Option Exercise | 7,982 | $0 | 2/15/2024 | View on chart |
| DAN | ▲ Buy | Option Exercise | 223 | $0 | 2/15/2024 | View on chart |
| DAN | ▲ Buy | Option Exercise | 6,578 | $0 | 2/16/2023 | View on chart |
| DAN | ▲ Buy | Option Exercise | 159 | $0 | 2/16/2023 | View on chart |
| DAN | ▲ Buy | Option Exercise | 5,877 | $0 | 2/10/2022 | View on chart |
| DAN | ▲ Buy | Option Exercise | 95 | $0 | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
LyondellBasell Faces Dividend Cuts and New Analyst Coverage
Recent reports note that LyondellBasell reduced its dividend while maintaining a 5.3% yield, prompting discussion of the sustainability of its high payout. Analysts at RBC and Barclays have kept an upbeat outlook but lowered their price targets to $68 and $66 respectively, citing the upcoming quarterly earnings as a key catalyst. The mix of dividend concerns and revised targets adds uncertainty ahead of the earnings release.
LyondellBasell Faces Dividend Cuts and New Analyst Coverage. Recent reports note that LyondellBasell reduced its dividend while maintaining a 5.3% yield, prompting discussion of the sustainability of its high payout. Analysts at RBC and Barclays have kept an upbeat outlook but lowered their price targets to $68 and $66 respectively, citing the upcoming quarterly earnings as a key catalyst. The mix of dividend concerns and revised targets adds uncertainty ahead of the earnings release.